Advertisement

Search Results

Advertisement



Your search for early matches 10012 pages

Showing 1251 - 1300


pancreatic cancer

Study Finds Precursor Pancreatic Lesions Occur Frequently in Healthy Human Pancreases

Pancreatic cancer is a rare disease, accounting for about 3% of all cancers in the United States. It is the deadliest of all solid malignancies, accounting for about 7% of all cancer deaths each year, and carries a 5-year survival rate of just 11.5%. According to the American Cancer Society, in...

breast cancer

Pathologic Complete Response as Surrogate for Event-Free and Overall Survival in Neoadjuvant Trials in HER2-Positive Early Breast Cancer

In a study reported in the Journal of Clinical Oncology, Squifflet et al found that pathologic complete response (pCR) was a weak surrogate for event-free and overall survival in neoadjuvant trials of anti-HER2 therapy in patients with HER2-positive early breast cancer. Study Details In the study,...

survivorship

Healthy Lifestyles May Be Associated With Reduced Mortality Risk in Pediatric Cancer Survivors

Researchers have provided strong evidence that a healthy lifestyle may significantly reduce mortality in adults who have survived pediatric cancer, according to a new study published by Dixon et al in The Lancet. The findings are among the first to reveal that the specific primary causes of...

global cancer care

Surgeon and Cancer Researcher Kelly M. McMasters, MD, PhD, Celebrates the ‘Miracle of Translational Science’

In this installment of our Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Kelly M. McMasters, MD, PhD, who, for the past 27 years, has directed a basic and translational science lab studying adenovirus-mediated cancer gene therapy and melanoma biomarkers....

Nobel Laureate Carolyn R. Bertozzi, PhD, to Receive 2023 AACR Award for Outstanding Achievement Cancer Research

The American Association for Cancer Research (AACR) will honor Nobel Laureate Carolyn R. Bertozzi, PhD, with the 2023 AACR Award for Outstanding Achievement in Chemistry in Cancer Research during the 2023 AACR Annual Meeting on April 14–19 in Orlando, Florida. Dr. Bertozzi’s award lecture will be...

lung cancer

Genetics Likely Caused My Small Cell Lung Cancer

When I was diagnosed with lung cancer, in 2007, I asked the physician not to tell me the type, stage, or prognosis. I was about to start nursing school and was aware enough about the disease to know that not many people survived. I’ve since discovered that I had stage 3B small cell lung cancer,...

breast cancer

Abemaciclib Expanded Indication for Adjuvant Use in HR-Positive, HER2-Negative, Node-Positive Early Breast Cancer

On March 3, 2023, abemaciclib was approved for use with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of patients with hormone receptor (HR)-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence.1 Abemaciclib was previously approved...

kidney cancer

Effect of Smoking Cessation After Diagnosis of Renal Cell Carcinoma on Disease Progression and Survival Outcomes

In a Russian single-institution prospective cohort study reported in the Journal of Clinical Oncology, Sheikh et al found that quitting smoking after a diagnosis of renal cell carcinoma (RCC) was associated with improved disease progression and survival outcomes among patients. Study Details The...

solid tumors

EAU and ASCO Release Collaborative Guidelines on Penile Cancer

Penile cancer is a rare disease with an incidence that is rising globally. Driven by a goal to offer clinicians and patients guidance on the management of this rare condition, ASCO collaborated with the European Association of Urology (EAU) to develop new guidelines on its diagnosis and treatment....

Lymphoma Research Foundation Establishes Kanti R. Rai, MD, Clinical Scholar Program for the Ongoing Study of CLL

The Lymphoma Research Foundation (LRF) has announced the creation of the Kanti R. Rai, MD, Clinical Scholar Program to fund the ongoing study of lymphoma and chronic lymphocytic leukemia (CLL). Established in recognition of the global leadership of Kanti R. Rai, MD, in the field of lymphoma and CLL ...

breast cancer

Which Patients With Breast Cancer Can Omit Radiotherapy?

Although advances in radiation therapy have rendered this treatment modality more tolerable, they have not completely eliminated the burden of radiation-related toxicity. In an ideal setting, clinicians would be able to identify patients whose risk of recurrence is sufficiently low that they can...

breast cancer
immunotherapy

Early-Stage Triple-Negative Breast Cancer: Optimizing Therapy

The management of early-stage triple-negative breast cancer has been evolving at a fast pace, thanks largely to the discovery that immune checkpoint blockade can be effective in this subtype. At the 2023 Miami Breast Cancer Conference, Priyanka Sharma, MD, Professor of Medicine, University of...

hematologic malignancies
immunotherapy

Interferon Alfa-2b May Substantially Increase Survival in Patients With Lymphomatoid Granulomatosis

Researchers have demonstrated that patients with low-grade lymphomatoid granulomatosis who were treated with the immunotherapy interferon alfa-2b may survive for a median of 20 years after diagnosis, according to a novel study published by Melani et al in The Lancet Haematology. The findings...

NCCN Names UChicago Medicine Comprehensive Cancer Center as 33rd Member Institution

The National Comprehensive Cancer Network (NCCN) announced that the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) has been named its newest member institution. With the addition, there are now 33 academic centers across the United States that have multidisciplinary subject...

head and neck cancer

Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Julie E. Bauman, MD, MPH, and colleagues found that the combination of the antihepatocyte growth factor antibody ficlatuzumab and cetuximab was active in patients with cetuximab-resistant, recurrent or metastatic head and neck...

issues in oncology

HHS Releases National Cancer Plan to Advance the Goals of the Cancer Moonshot and Improve Outcomes for All Patients

On April 3, the U.S. Department of Health and Human Services (HHS) released a National Cancer Plan, which calls for collaboration to realize the objectives laid out in the Cancer Moonshot to reduce cancer mortality by at least 50% over the next 25 years and “end cancer as we know it.” Developed by...

leukemia

Menin Inhibitors Under Study in KMT2A-Rearranged or NPM1-Mutant Acute Myeloid Leukemia

Menin inhibitors are making inroads in the treatment of acute myeloid leukemia (AML). These drugs selectively target KMT2A-rearranged or NPM1-mutant AML, and early studies suggest they will be a welcome addition for patients with these aberrations. KMT2A rearrangements occur in about 5% of patients ...

gynecologic cancers

Effect of Insurance Status on Racial and Ethnic Inequities in the Diagnosis of Advanced-Stage Cervical Cancer

In a study reported in JAMA Network Open, Holt et al found that health insurance status was a substantial mediator in the diagnosis of advanced-stage vs early-stage cervical cancer across ethnicity and race in patients from the United States. Study Details The retrospective, cross-sectional,...

gynecologic cancers

Addition of Immunotherapy to Chemotherapy Regimen May Increase Progression-Free Survival in Patients With Advanced or Recurrent Endometrial Cancer

Adding immunotherapy to standard chemotherapy may result in significantly longer progression-free survival for patients with advanced or recurrent endometrial cancer, according to the findings from two novel studies presented by Eskander et al and Mirza et al at the Society of Gynecologic Oncology...

gynecologic cancers

Atezolizumab May Be an Effective Primer for Chemoradiation in Patients With Locally Advanced Cervical Cancer

After comparing the efficacy of the anti–PD-L1 inhibitor atezolizumab prior to and concurrently with chemoradiation, researchers have indicated favorable outcomes for 2-year disease-free survival and demonstrated evidence of improved immunogenicity with neoadjuvant atezolizumab in patients with...

breast cancer
geriatric oncology

Change in Frailty Status Among Older Patients Undergoing Locoregional Therapy for Early-Stage Breast Cancer

In a cohort study reported in a research letter in JAMA Surgery, Minami et al found that frailty status worsened in a sizable proportion of older patients receiving locoregional therapy—including lumpectomy or mastectomy—for early-stage breast cancer. Baseline robust status and mastectomy were...

gastroesophageal cancer

Lower-Income Patients With Early-Stage Esophageal Adenocarcinoma May Face Disparities in Cancer Care and Higher Mortality Rates

Patients with early-stage esophageal adenocarcinoma from lower-income households may be significantly less likely to receive a potentially life-saving treatment and may be more likely to die from the disease, according to a new study published by Geng et al in Clinical Gastroenterology and...

Three Models Testing Ways to Lower Drug Costs Outlined in Health and Human Services Report

On February 14, 2023, the Centers for Medicare & Medicaid Services (CMS) announced that the Secretary of the Department of Health and Human Services (HHS) selected three models aiming to address high prescription drug costs for testing by the Center for Medicare and Medicaid Innovation (CMMI)....

lung cancer
genomics/genetics

Sotorasib Improves Progression-Free Survival vs Docetaxel in Previously Treated Advanced NSCLC With KRAS G12C Mutation

As reported in The Lancet by ­Adrianus Johannes de Langen, MD, PhD, of the Netherlands Cancer Institute, Amsterdam, and colleagues, the phase III CodeBreaK200 trial has shown a small but significant improvement in progression-free survival with sotorasib vs docetaxel in previously treated advanced...

multiple myeloma
immunotherapy

Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma

As reported in The New England Journal of Medicine by Paula Rodriguez-Otero, MD, PhD, of Clínica Universidad de Navarra, Pamplona, Spain, and colleagues, an interim analysis of the phase III KarMMa-3 trial has shown superior progression-free survival with the B-cell maturation antigen–directed...

colorectal cancer

10 Facts About Colorectal Cancer From the Colorectal Cancer Alliance

March is widely recognized worldwide as Colorectal Cancer Awareness month. Several advocacy groups and professional organizations recognize Colorectal Cancer Awareness month by promoting screening for eligible individuals and working to increase awareness. Here, the Colorectal Cancer Alliance, an...

issues in oncology

Racial/Ethnic Disparities in All-Cause and Cardiovascular Mortality Among U.S. Patients With Cancer

In an analysis reported in JACC: CardioOncology, Cenjing Zhu, MPhil, of the Department of Chronic Disease Epidemiology, Yale University, and colleagues found that Black patients with cancer in the United States were at increased risk of all-cause mortality and cardiovascular (CVD) mortality...

colorectal cancer

Colorectal Cancer Rates Are Rising in Younger Adults, Shifting to More Advanced Disease Across All Ages

According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer and the third most common cause of cancer-related death in both men and women in the United States. However, it ranks second in cancer-related deaths overall and is the leading cause of cancer...

prostate cancer

TALAPRO-2: Talazoparib Plus Enzalutamide Extends Radiographic Progression–Free Survival in Metastatic Castration-Resistant Prostate Cancer

The addition of the poly (ADP ribose) polymerase (PARP) inhibitor talazoparib to the androgen receptor signaling inhibitor enzalutamide achieved a statistically significant and clinically meaningful improvement in radiographic progression–free survival compared with placebo plus enzalutamide as...

Carl H. June, MD, FAACR, to Be Honored With 2023 AACR Award for Lifetime Achievement in Cancer Research

The American Associationfor Cancer Research (AACR) will award Carl H. June, MD, FAACR, Fellow of the AACR Academy, with the 2023 AACR Award for Lifetime Achievement in Cancer Research during the 2023 AACR Annual Meeting, April 14–19 in Orlando, Florida. Dr. June is the Richard W. Vague Professor in ...

lymphoma

Alex F. Herrera, MD, on Previously Untreated DLBCL: Circulation Tumor DNA and Risk Profiling

Alex F. Herrera, MD, of the City of Hope National Medical Center, discusses results from the POLARIX study, which showed that circulating tumor DNA (ctDNA) analysis has prognostic value for patients with previously untreated diffuse large B-cell lymphoma. Patients who did not achieve 2.5 or...

breast cancer

Adjuvant Accelerated Partial-Breast Irradiation vs Whole-Breast Irradiation in Early Breast Cancer: 10 Year Outcomes of Phase III Study

As reported in The Lancet Oncology by Vratislav Strnad, MD, PhD, of University Hospital Erlangen and Comprehensive Cancer Center Erlangen, Germany, and colleagues, 10-year outcomes in a phase III GEC-ESTRO (Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology) trial...

global cancer care

Early Exposure to Health-Care Inequities Sets the Stage for a Leadership Role in Global Oncology for Satish Gopal, MD, MPH

In this installment of The ASCO Post’s Global Oncology series, guest editor, Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Satish Gopal, MD, MPH, Director of the Center for Global Health at the National Cancer Institute (NCI). In this role, he oversees the development of initiatives and...

Northwell Health Names Richard D. Carvajal, MD, to Lead Medical Oncology Programs

Northwell Health has appointed Richard D. Carvajal, MD, a clinician and researcher in melanoma and early-phase drug development, as Deputy Physician-in-Chief and Director of Medical Oncology at the Northwell Health Cancer Institute. He also was named the R. J. Zuckerberg Chair in Medical Oncology....

Cleveland Clinic Opens New Cancer Center in Abu Dhabi

Cleveland Clinic has announced the opening of a new state-of-the-art cancer facility, named the Fatima bint Mubarak Center, at Cleveland Clinic Abu Dhabi. “[This] marks the next step in fulfilling our mission to provide compassionate, complex care in the United Arab Emirates [UAE)]” said Tom...

A Pioneering Oncologist, a Pilot, and a Choral Singer, Among Other Things

“There is and always has been, more to me than medicine. Ever since the university, I have loved flying. Ever since school, I have adored choral singing,” writes John F. Smyth, MD, in his memoir Taming the Beast: Memoirs of a Pioneering Cancer Physician. Dr. Smyth is Emeritus Professor of Medical...

issues in oncology

Walks on a Beach With an Inspiring Grandfather Led to a Career in Cancer Research and Drug Development for Vivek Subbiah, MD

In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Vivek Subbiah, MD, Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine Division, at The University of Texas MD Anderson Cancer Center, ...

prostate cancer

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...

Patricia M. LoRusso, DO, PhD (hc), Elected 2023–2024 AACR President-Elect

The members of the American Association for Cancer Research (AACR) have elected Patricia M. LoRusso, DO, PhD (hc), as the President-Elect for the 2023 to 2024 term. Dr. LoRusso will become President-Elect on Monday, April 17, during the Annual Business Meeting of Members at the AACR Annual Meeting...

solid tumors

Retroperitoneal Lymph Node Dissection for Early Metastatic Testicular Seminoma

In a phase II trial reported in the Journal of Clinical Oncology, Daneshmand et al found that first-line retroperitoneal lymph node dissection (RPLND) was associated with good outcomes in patients with testicular seminoma with clinically low-volume retroperitoneal lymphadenopathy. As stated by the...

issues in oncology

ACCC Releases 2022 Impact Report

The Association of Community Cancer Centers (ACCC)—which represents more than 34,000 multidisciplinary oncology practitioners—outlined successful programs and initiatives in 2022 that advanced oncology care, according to the ACCC's 2022 Impact Report. These new programs and initiatives included...

breast cancer

Understanding Fertility Issues in Young Patients With Breast Cancer

Young women with breast cancer have many concerns about their future fertility. How confident are you in discussing their chances of a future pregnancy, the effect of breast cancer treatment and fertility interventions on these offspring, and their risk of a compromised oncologic outcome after...

issues in oncology
covid-19

Trust in Cancer Information May Have Declined Among Black Individuals During COVID-19 Pandemic

Investigators have found that Black individuals’ trust in information provided by the government on cancer fell by almost 50% during the COVID-19 pandemic, according to a new study published by Bispo et al in the Journal of Health Communication. The investigators stressed the need to assess whether ...

head and neck cancer

Axitinib and Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma

In a single-center phase II trial reported in the Journal of Clinical Oncology, Renata Ferrarotto, MD, and colleagues found that the combination of axitinib and avelumab showed evidence of activity in patients with recurrent or metastatic adenoid cystic carcinoma. Study Details In the study, 28...

lung cancer
immunotherapy

Neoadjuvant Dual Immunotherapy Plus Chemotherapy Improves Patient Outcomes in Operable Lung Cancer

In the phase II NEOSTAR trial, adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic response in half of all treated patients with early-stage, resectable non–small cell lung cancer (NSCLC). New findings from the NEOSTAR study,...

lung cancer

Detection of Emphysema During Lung Cancer Screening

In an article published in Annals of the American Thoracic Society, James L. Mulshine, MD, and colleagues maintained that the high frequency of emphysema newly identified during low-dose computed tomography (CT) lung cancer screening presents an important opportunity to engage individuals with such ...

covid-19
issues in oncology

COVID-19 Vaccination Rates May Be Lower in Patients With Cancer Who Have Comorbidities, Certain Types of Cancer, and Specific Sociodemographic Factors

Investigators have found that patients undergoing treatment for cancer who have comorbidities, metastatic solid or non–B-cell hematologic malignancies, and those living in areas with lower levels of education and higher levels of unemployment may have lower rates of COVID-19 vaccination, according...

prostate cancer
issues in oncology

New Research Highlights the Negative Impact of Continued Exclusion of Patients With African Ancestry From Research on Cancer Genomics

Researchers have revealed how the lack of genomic research for individuals with African ancestry—particularly those from the Sub-Saharan region—may be hampering efforts to reduce disparities for patients with prostate cancer, according to a new study published by Gheybi et al in JNCCN–Journal of...

supportive care

Involving Hospitalists in Inpatient Cancer Care May Reduce Patient Stays, Oncologist Stress

Introducing hospitalists to cancer care comanagement may be associated with decreased lengths of hospital stays for patients, increased inpatient hospital capacity, and reduced stress levels among oncologists—all while maintaining high-quality inpatient care, according to a new study published by...

prostate cancer

Delaying Treatment for Patients With Localized Prostate Cancer May Not Increase Mortality Risk, ProtecT Trial Shows

Patients with prostate cancer who undergo active monitoring may experience the same 15-year survival rates as those who undergo radiotherapy or surgery, according to new findings published by Hamdy et al in The New England Journal of Medicine and simultaneously presented at the 2023 European...

Advertisement

Advertisement




Advertisement